Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Research output: Contribution to journalArticle

Standard

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

AU - Gustbée, Emma

AU - Tryggvadottir, Helga

AU - Markkula, Andrea

AU - Simonsson, Maria

AU - Nodin, Björn

AU - Jirström, Karin

AU - Rose, Carsten

AU - Ingvar, Christian

AU - Borgquist, Signe

AU - Jernström, Helena

PY - 2015

Y1 - 2015

N2 - The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).

AB - The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).

U2 - 10.1186/s12907-015-0008-2

DO - 10.1186/s12907-015-0008-2

M3 - Article

VL - 15

JO - BMC Clinical Pathology

T2 - BMC Clinical Pathology

JF - BMC Clinical Pathology

SN - 1472-6890

M1 - 8

ER -